The financial burden of using <scp>O</scp>ncotype <scp>D</scp>x for patients with lymph node‐negative and estrogen receptor‐positive breast cancer in <scp>A</scp>ustralia

Sakata, Shinichiro; Cronk, Michelle F.

doi:10.1111/ajco.12077

Cited by 4 publications

(1 citation statement)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Hospital costs for chemotherapy alone have been reported to be AUD$15,000 per breast cancer patient, even exclusive of adverse events. 33 We attempted to account for all breast cancer-related costs, and set a wide range for the sensitivity analysis to compensate for this. BRCA carrier status can also be used to guide cancer treatment, including the use of poly (ADP-ribose) polymerase (PARP) inhibitors, which prolong progression-free survival in BRCAassociated ovarian 34 and metastatic breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers

Petelin

Hossack

Shanahan

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers

Petelin

Hossack

Shanahan

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer

Degeling

Kosmider

et al. 2021

PharmacoEconomics

View full text Add to dashboard Cite

Inpatient care burden due to cancers in Anhui, China: a cross-sectional household survey

et al. 2016

View full text Add to dashboard Cite

BackgroundThe financial burden of cancers has profound effects and there is a clear need to explore the issue from different perspectives and for different population groups. This study aimed at investigating inpatient cancer care (ICC) burden in Anhui, a typical inland province of China.MethodsThe study collected data through a household survey conducted during April to November, 2014 using cluster-randomized sampling and a structured questionnaire administered face-to-face by trained interviewers.ResultsThe survey covered 60,678 urban and rural residents and 318 person-times of ICC during the past year. Age-adjusted annual person-times and days of ICC per thousand population added up to 4.24 and 76.78 respectively and urban residents showed significantly greater admission rates and length of stay than that of rural ones. Total ICC expenditures accounted for 13.30 % of all that of inpatient care for the whole population. Per-case direct and indirect costs of all types of cancers were estimated as 10365.1 and 929.9 RMB. Per-case total cost on ICC at township hospitals was 2142.3 RMB and at province level hospitals, 17133.0 RMB. Significant variations in per-case ICC expenditures also existed between patients with different household income and type of medical insurance systems, but patients suffering from different types of cancers. Out-of-pocket payment due to ICC turned out to be catastrophic for 20.6 % of all cancer patients and 65.2 % for other medical insurance, 45.6 % for enrollees of urban and rural medical insurance, 43.2 % for the 65 to 74 years old. Multi regression revealed statistically significant association between ICC costs and education, reimbursement ratio, household income and level of hospital.ConclusionsCancers characterize low incidence, moderate service use and high expenses. There exist substantial differences between subgroups and part of these variations cannot be explained by pathological factors. ICC expenses are catastrophic in nature to a large part of patients. There is a clear need for more effectively regulating cancer-related medical practices and service seeking behaviors.Electronic supplementary materialThe online version of this article (doi:10.1186/s12889-016-2995-z) contains supplementary material, which is available to authorized users.

show abstract

The financial burden of using Oncotype Dx for patients with lymph node‐negative and estrogen receptor‐positive breast cancer in Australia

Cited by 4 publications

References 6 publications

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer

Inpatient care burden due to cancers in Anhui, China: a cross-sectional household survey

Contact Info

Product

Resources

About